1 Kelland LR.An update on satraplatin:the first orally available platinum anticancer drug [J].Expert Opin Investing Drugs, 2000;9:1373-1382. 2 Kelland LR, Abel G, McKeageMJ, et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV):an orally active platinum drug[J].Cancer Res, 1993;53:2581-2586. 3 Giandomenico CM, AbramsMJ, Murrer BA, et al.Carboxylation of kinetically Inert platinum (IV) hydroxy complexes.An entree into orally active platinum (IV) antitumor agents[J].Inorg Chem, 1995;34:1015-1021. 4 Yan DM, Li WJ, Peng XY.Recent advances of platinum-containing anticancer drugs[J].China Pharmacy, 2005;16:1022-1025. 5 Li WJ, Ma ZY.Satraplatin:new-generation platinum antitumor agent[J].Chin J Mod Appl Pharmacy, 2004;21:25-27. 6 Mckeagf MJ.New-generation platinum drugs in the treatment of cisplatin-resistant cancers [J].Expert Opin Investig Drugs, 2005;14:1033-1046. 7 Li WJ, Peng XY, Ma ZY, Zheng YX.The preclinical antitumor study of satraplatin[J].Chin New Drug J, 2003;12:643-645. 8 Sternberg CN, Whelan P, Hetherington J, et al.Genitourinary Tract Group of the EORTC.Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs.Prednisone alone in Patients with Hormone-Refractory Prostate Cancer[J].Oncology, 2005; 68:2-9. 9 Latif T, Wood L, Connell C, et al.Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)[J].Invest New Drugs, 2005;23:79-84. 10 Zaffaroni N, Silvestrini R, Orlandi L, et al.Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and-resistant human ovarian cells [J].Br J Cancer, 1998;77:1378-1385. 11 Faivre S, Chan D, Salinas R, et al.DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells[J].Biochem Pharmacol, 2003;66:225-237. 12 Cummings BS, Schnellmann RG.Cisplatin-induced renal cell apoptosis:caspase-3-dependent and-independent pathways[J]. J Pharmacol Exp Ther, 2002;302:8-17. 13 Kim JS, Lee JM, Chwae YJ, et al.Cisplatin-induced apoptosis in Hep3B cells:mitochondria-dependent and-independent pathways[J].Biochem Pharmacol, 2004;67:1459-1468. 14 OrmerodMG, O'Neill C, Rovertson D, et al.Cis-diamminedichloroplatinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines[J]. Cancer Chemother Pharmacol, 1996;37:463-471. 15 O'Neill CF, Ormerod MG, Robertson D, et al.Apoptotic and non apoptotic cell death induced by cis and trans analogues of a novel ammine (cy clohexylamine) dihydroxodichloroplatinum (IV) complex[J].Br J Cancer, 1996;74:1037-1045. 16 O'Neill CF, Koberle B, Masters JRW, et al.Gene-specific repair of Pt DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin[J].Br J Cancer, 1999; 81:1294-1303. 17 Ormerod MG, Orr RM, Peacock JH.The role of apoptosis in cell killing by cisplatin:a flow cytometric study[J].Br J Cancer, 1994;69:93-100. 18 Sorenson CM, Eastman A.Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity:role of G2 arrest and DNA double-strand breaks[J].Cancer Res, 1988;48:4484-4488. 19 Sorenson CM, Eastman A.Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells[J].Cancer Res, 1988;48:6703-6707. 20 Vaisman A, Varchenko M, Said I, et al.Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity[J].Cytometry, 1997;27:54-64. 21 Cohen GM.Caspase:The executioners of apoptosis [J].Biochem J, 1997;326:1-16. |